Cancers of the corpus uteri on the Côte-d'Or 1982-1990. Incidence, clinical stage and survival

In the French administrative "departement" of Côte-d'Or, between 1982 and 1990, the crude incidence rate and the age-adjusted world standardised incidence rate (ASR) for corpus uteri cancer were respectively 16.0 +/- 0.8 and 10.7 +/- 0.6 per 100,000 women per year. The incidence incre...

Full description

Saved in:
Bibliographic Details
Published inBulletin du cancer Vol. 81; no. 8; p. 691
Main Authors Chaplain, G, Cuisenier, J, Milan, C, Smail, M, Janoray, P, Collin, F, Déchelotte, D, Michiels-Marzais, D, Jahier, J, Michiels, R
Format Journal Article
LanguageFrench
Published France 01.08.1994
Subjects
Adult
Age Factors
Aged
Aged, 80 and over
Female
France - epidemiology
Humans
Incidence
Middle Aged
Neoplasm Staging
Prognosis
Survival Rate
Uterine Neoplasms - epidemiology
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
France
Online AccessGet more information

Cover

More Information
Summary:In the French administrative "departement" of Côte-d'Or, between 1982 and 1990, the crude incidence rate and the age-adjusted world standardised incidence rate (ASR) for corpus uteri cancer were respectively 16.0 +/- 0.8 and 10.7 +/- 0.6 per 100,000 women per year. The incidence increased after 50 years of age, reaching a maximum of 66.7 per 100,000 women per year at the age of 70-74 and thereafter declined. Ninety-six percent of the patients were older than 50. The 5- and 10-year crude survival rates (all histologic types) were 66 +/- 3% and 61 +/- 4%. The 5- and 10-year relative survival rates were 76%. Histologic types were specified in 99.7% of cases, categorized as follows: 92.7% carcinomas (333 cases), 6.7% sarcomas (24 cases) and 0.3% lymphoma (one case). Carcinomas were clinically evaluated according to FIGO staging: stage I: 61.4% (205 cases); stage II: 7.7% (59 cases); stage III: 7.8% (26 cases); stage IV: 6.6% (22 cases) and unspecified stage: 6.6% (22 cases). The ASR by stage, were 6.4 +/- 0.5 (stage I); 0.8 +/- 0.2 (stage II); 1.3 +/- 0.2 (stages III and IV); 0.6 +/- 0.2 (unspecified stage). The 5-year relative survival rates related to FIGO stage were 90% (stage I); 85% (stage II); 25% (stage III) and 0% (stage IV). Elderly patients (> 75) had significantly lower survival rates. With respect to localized disease (stages I and II) the relative risk of death associated with age older than 75 was 4.9. The 5-year relative survival rate of patients with sarcoma was 37%.
ISSN:0007-4551